Introduction: Malignant breast neoplasms have a high incidence and represent significant causes of morbidity and mortality among the female population. Therefore, to ensure screening and early initiation of treatment, the Brazilian Ministry of Health, in 2014, established through the Unified Health System (SUS) the provision of free mammography exams for women of all age groups, prioritizing those aged 50 to 69 years, in accordance with WHO recommendations. Thus, it is essential to analyze the actual impact of early screening for this disease. Objectives: To analyze the temporal trend and projections of mortality from malignant breast neoplasms in Brazil between 2010 and 2021. Methods: This is a cross-sectional, observational, and retrospective study that utilized secondary data from the Department of Informatics of the Unified Health System (DATASUS) regarding mortality from malignant breast neoplasms and outpatient production of mammography exams. The number of deaths was used to calculate the mortality rate. The collected data were organized into tables using Excel®. For modeling and forecasting, the ARIMA (AutoRegressive Integrated Moving Average) model was employed, which is suitable for non-stationary time series. Results: Between 2010 and 2021, a total of 190,344 deaths were recorded in Brazil. The year with the highest number of deaths was 2021, with 18,361 (9.64%) deaths, while the year with the lowest number was 2010, with 12,853 (6.75%) deaths. Regarding educational level, the highest number of deaths occurred among individuals with no formal education or incomplete elementary education (1 to 7 years), totaling 75,302 (39.56%). The lowest numbers were observed among those with no education — 15,265 (8%) — and among those who had completed high school or higher education (12 years or more) — 24,072 (12.64%). Temporal analysis demonstrated an upward trend until 2019, followed by a decline through the end of 2020, after which an upward trend was again observed. The forecast (Figure 1) performed using the ARIMA model showed monthly values and trends that were either below or followed the pattern recorded throughout the years presented in the real mortality rate time series (Figure 2) Conclusion: The introduction of mammography within the Unified Health System (SUS) aimed to reduce breast cancer mortality through early diagnosis. However, an increase or stabilization in mortality rates has been observed over the years. This may be explained by the greater effectiveness in diagnosing breast cancer through the use of mammography, thereby reducing the underreporting of the disease. Furthermore, an inverse relationship between educational level and the number of deaths from breast cancer is evident, highlighting the significant impact of patients' socioeconomic conditions on disease prognosis.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
